The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae635 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Zhihe Chen und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Brain, Aging, Cognition. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support.
Abstract (Originalsprache)
Introduction
An observational study suggested sodium-glucose cotransporter 2 (SGLT2) inhibitors might promote healthy aging. However, whether brain-related phenotypes mediate this association is still a question. We applied Mendelian randomization (MR) to investigate the effect of SGLT2 inhibition on chronological age, biological age, and cognition and explore the mediation effects of brain imaging-derived phenotypes (IDPs).
Methods
We selected genetic variants associated with both expression levels of SLC5A2 (Genotype-Tissue Expression and eQTLGen data; n = 129 to 31 684) and hemoglobin A1c (HbA1c) levels (UK Biobank; n = 344 182) and used them to proxy the effect of SGLT2 inhibition. Aging-related outcomes, including parental longevity (n = 389 166) and epigenetic clocks (n = 34 710), and cognitive phenotypes, including cognitive function (n = 300 486) and intelligence (n = 269 867) were derived from genome-wide association studies. Two-step MR was conducted to explore the associations between SGLT2 inhibition, IDPs, and aging outcomes and cognition.
Results
SGLT2 inhibition was associated with longer father's attained age [years of life increase per SD (6.75 mmol/mol) reduction in HbA1c levels = 6.21, 95% confidence interval (CI) 1.27-11.15], better cognitive function (beta = .17, 95% CI 0.03-0.31), and higher intelligence (beta = .47, 95% CI 0.19-0.75). Two-step MR identified 2 IDPs as mediators linking SGLT2 inhibition with chronological age (total proportion of mediation = 22.6%), where 4 and 5 IDPs were mediators for SGLT2 inhibition on cognitive function and intelligence, respectively (total proportion of mediation = 61.6% and 68.6%, respectively).
Conclusion
Our study supported that SGLT2 inhibition increases father's attained age, cognitive function, and intelligence, which was mediated through brain images of different brain regions. Future studies are needed to investigate whether a similar effect could be observed for users of SGLT2 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Shan…
- MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Oakfield House, Bristol BS8 2BN, UK.
- SJTU-Ruijin-UIH Institute for Medical Imaging Technology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administration Region 999077, China.
ORCID-Profile: Tiange Wang, Zhiyun Zhao, Min Xu, Yu Xu, Jieli Lu, Guang Ning, Weiqing Wang, Shan Luo, Shiu Lun Au Yeung, Yufang Bi, Jie Zheng
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support
- Innovative Research Team of High-level Local Universities in Shanghai
- Shanghai Municipal Education Commission–Gaofeng Clinical Medicine Grant Support
Zitieren
APA
Chen, Z., Wu, X., Yang, Q., Zhao, H., Ying, H., Liu, H., Wang, C., Zheng, R., Lin, H., Wang, S., Li, M., Wang, T., Zhao, Z., Xu, M., Chen, Y., Xu, Y., Lu, J., Ning, G., Wang, W., …, & Zheng, J. (2025). The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae635
Vancouver
Chen Z, Wu X, Yang Q, Zhao H, Ying H, Liu H, et al. The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae635
BibTeX
@article{Chen2025,
author = {Chen, Zhihe and Wu, Xueyan and Yang, Qianqian and Zhao, Huiling and Ying, Hui and Liu, Haoyu and Wang, Chaoyue and Zheng, Ruizhi and Lin, Hong and Wang, Shuangyuan and Li, Mian and Wang, Tiange and Zhao, Zhiyun and Xu, Min and Chen, Yuhong and Xu, Yu and Lu, Jieli and Ning, Guang and Wang, Weiqing and Luo, Shan and Au Yeung, Shiu Lun and Bi, Yufang and Zheng, Jie},
title = {The Effect of SGLT2 Inhibition on Brain-related Phenotypes and Aging: A Drug Target Mendelian Randomization Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae635}
}
EUVIMED